Change over period: —
NSE · NEULANDLAB
NEULAND LAB.
-10.6% from the 52-week high · +85.7% above the low
Neuland Laboratories Ltd. engages in the manufacture and export of bulk pharmaceutical ingredients and intermediates for the generics industry. The company is headquartered in Hyderabad, Telangana and currently employs 1,521 full-time employees. The firm is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets. The firm operates through manufacture of active pharmaceutical ingredients and allied services. The firm has two business verticals: generic drug substances (GDS) and custom manufacturing solutions (CMS). Its products and services include Levetiracetam, Mirtazapine, Ciprofloxacin, Enalapril, Sotalol, Labetalol and Custom Manufacturing Services. The Company’s capabilities include FBRM, research and development, peptide laboratory, poly block reactors, laboratory reactors, heating and cooling systems, hazardous and wet laboratory, PID Laboratory Unit-III, PID Laboratory B-S Unit-I, and other lab equipment. The firm has 3 manufacturing facilities and one R&D facility in Hyderabad.
The short version. NEULAND LAB. reported revenue of ₹450 crore for Sep 2026, down 12.5% from a year earlier. Net profit was ₹52 crore (down 46.4% year on year). Return on equity was 19.4% in Mar 2026. Promoter holding was 32.26% in Sep 2026, down 0.42 points over 8 quarters.
1 · The price
How has the stock traded?
NEULAND LAB. trades 10.6% below its 52-week high and 85.7% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹450 cr.
Sep 2026 net profit of ₹52 cr.
7.3 pts lower than a year earlier.
Revenue compounded at 19.6% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 450 | 642 | 776 | 440 | 514 | 293 | 328 | 398 |
| Net profit | 52 | 148 | 213 | 41 | 97 | 14 | 28 | 102 |
| Net margin % | 11.5 | 23.0 | 27.4 | 9.2 | 18.8 | 4.7 | 8.5 | 25.5 |
| EPS (₹) | 40.24 | 115.1 | 165.76 | 31.62 | 75.49 | 10.83 | 21.67 | 79.18 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2023 | 1477 | 1559 | 1191 | 951 | 937 | 763 | 667 |
| Net profit | 364 | 260 | 300 | 164 | 64 | 81 | 16 | 16 |
| Net margin % | 18.0 | 17.6 | 19.3 | 13.7 | 6.7 | 8.6 | 2.1 | 2.5 |
| EPS (₹) | 283.71 | 202.74 | 233.89 | 127.45 | 49.74 | 62.85 | 12.63 | 12.82 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 19.4% in Mar 2026; debt to equity is 0.10.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 19.4 | 17.1 | 23.4 | 16.4 |
| Return on capital % | 23.1 | 20.7 | 29.6 | 20.1 |
| EBITDA margin % | 29.4 | 28.1 | 30.2 | 23.4 |
| Net margin % | 17.7 | 17.4 | 19.1 | 13.6 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 19.6% | 16.6% |
| Profit CAGR | 30.6% | 35.2% |
4 · The owners
Who holds it, and are they adding?
Down 0.42 pts over 8 quarters.
Down 1.93 pts over 8 quarters.
Up 7.18 pts over 8 quarters.
+43 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 32.68 | 32.67 | 32.67 | 32.64 | 32.63 | 32.63 | 32.62 | 32.26 | -0.42 |
| FII | 23.86 | 22.11 | 21.69 | 20.6 | 20.9 | 20.46 | 21.08 | 21.93 | -1.93 |
| DII | 9.08 | 10.97 | 11.57 | 13.54 | 14.71 | 15.84 | 16.51 | 16.26 | +7.18 |
| Public | 33.98 | 33.84 | 33.67 | 32.81 | 31.76 | 31.07 | 29.79 | 29.55 | -4.43 |
Mutual fund holdings · Oct 2026
128 schemes hold this stock
85 the month before.
- LIC MF HEALTHCARE FUND5.83% of NAV
- Bajaj Finserv Healthcare Fund3.41% of NAV
- LIC MF SMALL CAP FUND3.28% of NAV
- LIC MF FLEXI CAP FUND3.21% of NAV
- LIC MF MID CAP FUND3.15% of NAV
- HDFC Pharma and Healthcare Fund2.96% of NAV
- HDFC MNC Fund2.88% of NAV
- SAMCO ELSS TAX SAVER FUND2.85% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for NEULAND LAB. are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about NEULAND LAB.
What is the NEULAND LAB. share price?
NEULAND LAB. (NEULANDLAB) last closed at ₹21,105.00, down 1.63% on the day. Its 52-week range is ₹11,555.00 to ₹23,995.00.
What is the market cap of NEULAND LAB.?
NEULAND LAB. has a market capitalisation of about ₹27,570 crore. Its price-to-earnings ratio is 61.3.
How are NEULAND LAB.'s latest results?
NEULAND LAB. reported revenue of ₹450 crore for Sep 2026, down 12.5% from a year earlier. Net profit was ₹52 crore (down 46.4% year on year). Return on equity was 19.4% in Mar 2026. Promoter holding was 32.26% in Sep 2026, down 0.42 points over 8 quarters.
Who owns NEULAND LAB.?
As of Sep 2026, shareholding was: Promoter 32.26%, FII 21.93%, DII 16.26%, Public 29.55%.
How many mutual funds hold NEULAND LAB.?
128 mutual fund schemes held NEULAND LAB. in October 2026. That compares with 85 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 18 Jul 2025 · Final Dividend - Rs. 12
- 12 Jul 2024 · Final Dividend - Rs. 14
- 11 Jul 2023 · Final Dividend - Rs. 10
- 14 Jul 2022 · Final Dividend - Rs. 5
- 29 Jun 2021 · Final Dividend - Rs. 3
- 10 Nov 2020 · Interim Dividend - Rs. 2
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.